KURA Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Kura Oncology, Inc. had $67.5M of revenue in fiscal 2025, up 25.2% on the year before.
Last close Β· Oct 23, 2026
$9.61
2.5%Hi! I read Kura Oncology, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+25.2%
Yes. Sales grew 25.2% last year.
Does it make a profit?
β412.9%
No. It lost money last year.
Does profit turn into cash?
β104.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Kura Oncology, Inc. had $67.5M of revenue in fiscal 2025, up 25.2% on the year before. Its operating margin was β449.9%, down 91.4Β pts: of every 100 in sales, about β450 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Kura Oncology, Inc. lost $279M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$70.7M in fiscal 2025, β104.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $2.4M and sold $3.8M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$2.4M
1 insider
Sold, 12 months
$3.8M
7 insiders
Of sales under plans
67%
$2.6M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Mollie LeoniChief Medical Officer | Sold plan | 28,802 | $10.75 | $0.3M | Form 4 |
| Sep 29, 2026 | Brian T. PowlChief Commercial Officer | Sold plan | 15,430 | $10.75 | $0.2M | Form 4 |
| Sep 29, 2026 | Kathleen FordChief Operating Officer | Sold plan | 3,668 | $10.75 | $0.0M | Form 4 |
| Sep 28, 2026 | Thomas James DoyleSVP, Finance & Accounting | Sold | 4,607 | $10.50 | $0.0M | Form 4 |
| Sep 28, 2026 | Teresa Brophy BairChief Legal Officer | Sold plan | 8,442 | $10.50 | $0.1M | Form 4 |
| Sep 28, 2026 | Mollie LeoniChief Medical Officer | Sold | 12,448 | $10.50 | $0.1M | Form 4 |
| Sep 28, 2026 | Brian T. PowlChief Commercial Officer | Sold plan | 17,020 | $10.53 | $0.2M | Form 4 |
| Sep 28, 2026 | Kathleen FordChief Operating Officer | Sold plan | 6,906 | $10.50 | $0.1M | Form 4 |
| Sep 24, 2026 | Francis BurrowsChief Scientific Officer | Sold | 20,726 | $10.83 | $0.2M | Form 4 |
| Aug 24, 2026 | Troy Edward WilsonPresident and CEO, Director | Bought | 100,000 | $12.39 | $1.2M | Form 4 |
| Aug 21, 2026 | Brian T. PowlChief Commercial Officer | Sold plan | 4,345 | $11.89 | $0.1M | Form 4 |
| Aug 19, 2026 | Teresa Brophy BairChief Legal Officer | Sold plan | 31,487 | $12.63 | $0.4M | Form 4 |
| Aug 17, 2026 | Troy Edward WilsonPresident and CEO, Director | Bought | 100,000 | $11.12 | $1.1M | Form 4 |
| Jun 18, 2026 | Mollie LeoniChief Medical Officer | Sold plan | 84,929 | $9.82 | $0.8M | Form 4 |
| May 21, 2026 | Brian T. PowlChief Commercial Officer | Sold plan | 10,000 | $11.00 | $0.1M | Form 4 |
| May 19, 2026 | Brian T. PowlChief Commercial Officer | Sold plan | 339 | $9.21 | $0.0M | Form 4 |
| May 19, 2026 | Kathleen FordChief Operating Officer | Sold plan | 2,257 | $9.08 | $0.0M | Form 4 |
| May 18, 2026 | Teresa Brophy BairChief Legal Officer | Sold plan | 2,256 | $9.38 | $0.0M | Form 4 |
| Jan 27, 2026 | Thomas James DoyleSVP, Finance & Accounting | Sold | 4,916 | $8.46 | $0.0M | Form 4 |
| Jan 27, 2026 | Teresa Brophy BairChief Legal Officer | Sold | 11,208 | $8.46 | $0.1M | Form 4 |
| Jan 27, 2026 | Brian T. PowlChief Commercial Officer | Sold | 6,414 | $8.46 | $0.1M | Form 4 |
| Jan 27, 2026 | Mollie LeoniChief Medical Officer | Sold | 8,180 | $8.46 | $0.1M | Form 4 |
| Jan 27, 2026 | Kathleen FordChief Operating Officer | Sold | 1,813 | $8.46 | $0.0M | Form 4 |
| Jan 27, 2026 | Francis BurrowsChief Scientific Officer | Sold | 1,311 | $8.46 | $0.0M | Form 4 |
| Dec 18, 2025 | Francis BurrowsChief Scientific Officer | Sold | 23,726 | $9.78 | $0.2M | Form 4 |
| Dec 9, 2025 | Faheem HasnainDirector | Sold plan | 10,000 | $10.98 | $0.1M | Form 4 |
| Nov 14, 2025 | Brian T. PowlChief Commercial Officer | Sold | 8,887 | $11.18 | $0.1M | Form 4 |
| Nov 14, 2025 | Thomas James DoyleSVP, Finance & Accounting | Sold | 4,539 | $11.18 | $0.1M | Form 4 |
| Nov 14, 2025 | Teresa Brophy BairChief Legal Officer | Sold plan | 8,804 | $11.18 | $0.1M | Form 4 |
| Nov 14, 2025 | Mollie LeoniChief Medical Officer | Sold | 15,485 | $11.18 | $0.2M | Form 4 |
| Nov 14, 2025 | Kathleen FordChief Operating Officer | Sold plan | 6,902 | $11.18 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Kura Oncology, Inc. has $658M more cash than debt.
Cash, debt and the ratios that show how comfortably Kura Oncology, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $518M | $438M | $424M | $727M | $667M |
| Debt incl. finance leases | β | $9.2M | $9.3M | $9.5M | $9.7M |
| Debt / equity | β | 0.0x | 0.0x | 0.0x | 0.1x |
| Interest coverage | β | β610.8x | β107.0x | β119.3x | β200.8x |
| Current ratio | 23.3x | 18.6x | 12.3x | 9.5x | 6.1x |
| Quick ratio | 23.3x | 18.6x | 12.3x | 9.5x | 6.1x |
| Total assets | $534M | $456M | $449M | $760M | $738M |
| Total liabilities | $27.4M | $36.0M | $51.7M | $347M | $564M |
| Shareholders' equity | $507M | $420M | $397M | $414M | $174M |
| Net debt (β = net cash) | β | β$429M | β$415M | β$718M | β$658M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Kura Oncology, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 4 / 7 | 4 / 7 | 4 / 7 | β / 6 | β / 6 | 1 / 7 | 5 / 8 | 2 / 8 |
| Accruals ratio | β3.2% | β8.4% | β8.5% | β3.9% | β4.5% | β4.4% | β5.2% | β6.1% | β51.0% | β28.6% |
| Altman Z'' | β | β | β | β | β | β | 12.20 | 6.16 | 1.45 | β2.37 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | β | β | β | β | β | $0.0M | $53.9M | $67.5M |
| Research and development | β | $26.4M | $46.8M | $47.8M | $60.4M | $84.7M | $92.8M | $115M | $170M | $251M |
| Operating income | β | β | β | β | β | β | β$140M | β$166M | β$193M | β$304M |
| Interest expense | $0.6M | $0.9M | $1.0M | $0.6M | $0.6M | $0.4M | $0.2M | $1.5M | $1.6M | $1.5M |
| Pretax income | β | β | β | β | β | β | β$136M | β$153M | β$172M | β$278M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $2.0M | $0.3M |
| Net income | β$27.6M | β$35.4M | β$60.4M | β$63.1M | β$89.6M | β$130M | β$136M | β$153M | β$174M | β$279M |
| Diluted EPS | β$1.47 | β$1.52 | β$1.72 | β$1.51 | β$1.69 | β$1.97 | β$2.03 | β$2.08 | β$2.02 | β$3.18 |
| Diluted shares | 0.02B | 0.02B | 0.04B | 0.04B | 0.05B | 0.07B | 0.07B | 0.07B | 0.09B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | β$25.3M | β$28.4M | β$48.7M | β$54.8M | β$69.8M | β$105M | β$110M | β$125M | $134M | β$64.1M |
| Capital expenditure | β | β | β | β | $2.2M | $1.1M | $0.6M | $0.2M | $0.5M | $6.6M |
| Free cash flow | β | β | β | β | β$72.0M | β$106M | β$111M | β$125M | $134M | β$70.7M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.2M | $0.6M | $0.8M | $0.8M | $0.8M | $1.0M |
| Stock-based compensation | $2.1M | $4.5M | $8.7M | $9.4M | $12.8M | $23.6M | $26.3M | $28.1M | $33.9M | $37.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $9.7M | $93.1M | $179M | $237M | $633M | $518M | $438M | $424M | $727M | $667M |
| Total debt | $7.3M | $7.1M | $7.5M | $7.5M | $7.3M | β | $9.2M | $9.3M | $9.5M | $9.7M |
| Current assets | $68.8M | $94.6M | $181M | $240M | $637M | $522M | $446M | $432M | $745M | $709M |
| Current liabilities | $5.5M | $10.0M | $13.6M | $15.6M | $26.0M | $22.5M | $24.1M | $35.3M | $78.7M | $117M |
| Inventory | β | β | β | β | β | β | β | β | $0.0M | $0.4M |
| Property and equipment, net | $0.0M | $0.0M | β | $0.0M | $2.0M | $2.7M | $2.5M | $1.9M | $1.7M | $7.9M |
| Total assets | $69.8M | $95.9M | $182M | $242M | $647M | $534M | $456M | $449M | $760M | $738M |
| Total liabilities | $12.9M | $16.0M | $21.4M | $23.2M | $36.3M | $27.4M | $36.0M | $51.7M | $347M | $564M |
| Shareholders' equity | $56.9M | $79.9M | $161M | $219M | $611M | $507M | $420M | $397M | $414M | $174M |
| Margins | ||||||||||
| Operating margin | β | β | β | β | β | β | β | β | β358.5% | β449.9% |
| EBITDA margin | β | β | β | β | β | β | β | β | β357.0% | β448.4% |
| Net margin | β | β | β | β | β | β | β | β | β322.9% | β412.9% |
| FCF margin | β | β | β | β | β | β | β | β | 248.4% | β104.8% |
| Returns | ||||||||||
| Return on capital employed | β | β | β | β | β | β | β32.4% | β40.1% | β28.4% | β48.9% |
| Return on equity | β48.5% | β51.8% | β50.2% | β33.3% | β21.6% | β23.3% | β29.3% | β37.3% | β42.9% | β94.8% |
| Return on assets | β39.5% | β42.8% | β43.5% | β29.8% | β20.2% | β22.1% | β27.4% | β33.7% | β28.8% | β37.2% |
| Return on tangible equity | β48.5% | β44.4% | β37.5% | β28.9% | β14.7% | β25.8% | β32.3% | β38.4% | β42.1% | β160.0% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β | β | β | β | 25.2% |
| FCF growth | β | β | β | β | β | β | β | β | β | β152.8% |
| Share count change | β | 24.3% | 51.4% | 19.2% | 26.5% | 25.0% | 1.0% | 9.3% | 17.7% | 1.8% |
| Financial health | ||||||||||
| Debt / equity | 0.1x | 0.1x | 0.0x | 0.0x | 0.0x | β | 0.0x | 0.0x | 0.0x | 0.1x |
| Interest coverage | β | β | β | β | β | β | β610.8x | β107.0x | β119.3x | β200.8x |
| Current ratio | 12.6x | 9.4x | 13.3x | 15.4x | 24.5x | 23.3x | 18.6x | 12.3x | 9.5x | 6.1x |
| Quick ratio | 12.6x | 9.4x | 13.3x | 15.4x | 24.5x | 23.3x | 18.6x | 12.3x | 9.5x | 6.1x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | β | β | β | β | β | 0.9% | 9.8% |
| Stock comp / revenue | β | β | β | β | β | β | β | β | 62.9% | 55.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 4.0 | 4.0 | 4.0 | β | β | 1.0 | 5.0 | 2.0 |
| Altman Z'' | β | β | β | β | β | β | 12.2 | 6.2 | 1.5 | β2.4 |
| Accruals ratio | β3.2% | β8.4% | β8.5% | β3.9% | β4.5% | β4.4% | β5.2% | β6.1% | β51.0% | β28.6% |
Source: SEC EDGAR XBRL filings (CIK 0001422143). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
